Skip to main content
Year archive

ERYTECH Pharma S.A. — 2023 filings

All 102 regulatory filings released by ERYTECH Pharma S.A. (ERYP) in 2023, sourced directly from the official regulator.

102 Filings
2023 Period
2023 filings (102)
Filing Released Lang
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 novembre 2023
Declaration of Voting Results & Voting Rights Announcements
2023-12-06 French
Monthly information related to total number of voting rights and shares composing the share capital - November 30, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-12-06 English
PHAXIAM Therapeutics fait le point sur ses activités et publie ses résultats du troisième trimestre 2023
Earnings Release 9M 2023
2023-11-14 French
PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
Earnings Release 9M 2023
2023-11-14 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2023
Declaration of Voting Results & Voting Rights Announcements
2023-11-07 French
Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-11-07 English
PHAXIAM Therapeutics obtient les autorisations nécessaires pour lancer son étude de phase 1 dans l’endocardite infectieuse causée par le Staphylococcus aureus
Regulatory Filings
2023-10-24 French
PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
Regulatory Filings
2023-10-24 English
TP ICAP Midcap initie à l’achat la couverture de PHAXIAM Therapeutics
Regulatory Filings
2023-10-23 French
TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation
Regulatory Filings
2023-10-23 English
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-10-23 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 septembre 2023
Declaration of Voting Results & Voting Rights Announcements
2023-10-23 French
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains
Earnings Release FY 2023
2023-10-09 English
PHAXIAM Therapeutics annonce un niveau de performance élevé de ses deux phages anti-Staphylococcus aureus sur des souches cliniques
Regulatory Filings
2023-10-09 French
PHAXIAM reçoit un avis de conformité du Nasdaq
Regulatory Filings
2023-10-04 French
PHAXIAM Receives Compliance Notice from Nasdaq
Regulatory Filings
2023-10-04 English
PHAXIAM Therapeutics et Vetophage annoncent une collaboration de recherche stratégique
Regulatory Filings
2023-10-03 French
PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration
Regulatory Filings
2023-10-03 English
Rapport Financier Semestriel 30 Juin 2023 PHAXIAM
Interim / Quarterly Report H1 2023
2023-09-26 French
RAPPORT FINANCIER SEMESTRIEL 30 JUIN 2023 PHAXIAM
Interim / Quarterly Report H1 2023
2023-09-26 French
PHAXIAM Provides Business and Financial Update For the First Half of 2023
Report Publication Announcement H1 2023
2023-09-21 English
PHAXIAM fait le point sur ses activités et publie ses résultats du premier semestre 2023
Earnings Release H1 2023
2023-09-21 French
PHAXIAM Therapeutics étend son portefeuille de phages à une nouvelle cible bactérienne résistante et agressive, Klebsiella pneumoniae
Regulatory Filings
2023-09-19 French
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
Regulatory Filings
2023-09-19 English
PHAXIAM Therapeutics annonce la finalisation des opérations de regroupement de ses actions
Share Issue/Capital Change
2023-09-18 French
PHAXIAM Therapeutics announces the completion of its reverse share split
Share Issue/Capital Change
2023-09-18 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 août 2023
Declaration of Voting Results & Voting Rights Announcements
2023-09-08 French
Monthly information related to total number of voting rights and shares composing the share capital _August 31, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-09-08 English
PHAXIAM Therapeutics publie son niveau de trésorerie, son nouveau calendrier financier et annonce sa participation à de prochaines conférences investisseurs
Report Publication Announcement
2023-09-05 French
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferences
Regulatory Filings
2023-09-05 English
Franchissement de seuils
Major Shareholding Notification
2023-08-28 French
Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-08-08 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2023
Declaration of Voting Results & Voting Rights Announcements
2023-08-08 French
PHAXIAM Therapeutics annonce le regroupement de ses actions
Share Issue/Capital Change
2023-07-27 French
PHAXIAM Therapeutics announces a reverse share split of its shares
Share Issue/Capital Change
2023-07-27 English
Franchissements de seuils et déclaration d'intention
Director's Dealing
2023-07-10 French
THE MARKET BACKS AKKADIAN PARTNERS AND CONDEMNS THE MERGER BETWEEN ERYTECH AND PHERECYDES
Legal Proceedings Report
2023-07-04 English
Franchissements de seuils et déclaration d'intention
Major Shareholding Notification
2023-07-04 French
LE MARCHÉ DONNE RAISON À AKKADIAN PARTNERS ET SANCTIONNE LA FUSION ENTRE ERYTECH ET PHERECYDES
Legal Proceedings Report
2023-07-04 French
Franchissement de seuils
Major Shareholding Notification
2023-07-03 French
Phaxiam Therapeutics annonce son nouveau code mnémonique sur Euronext et Nasdaq : PHXM
Regulatory Filings
2023-06-28 French
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
Delisting Announcement
2023-06-28 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 26 juin 2023
Declaration of Voting Results & Voting Rights Announcements
2023-06-27 French
Monthly information related to total number of voting rights and shares composing the share capital - June 26, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-06-27 English
ERYTECH et PHERECYDES annoncent leur fusion pour former PHAXIAM Therapeutics
M&A Activity
2023-06-26 French
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
M&A Activity
2023-06-26 English
ERYTECH annonce l'approbation de la fusion avec Pherecydes et communique les résultats de l'Assemblée Générale Mixte du 23 juin 2023
AGM Information
2023-06-23 French
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023
AGM Information
2023-06-23 English
AKKADIAN PARTNERS DOES NOT INTEND TO PARTICIPATE IN ERYTECH'S GENERAL MEETING ON 23 JUNE 2023 UNTIL THE LEGAL EXPERT'S REPORT HAS BEEN RELEASED
Legal Proceedings Report
2023-06-21 English
ERYTECH annonce qu'Akkadian poursuit sa tentative de déstabilisation avec l'introduction d'une nouvelle action judiciaire
Legal Proceedings Report
2023-06-20 French
ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit
Legal Proceedings Report
2023-06-20 English
AKKADIAN PARTNERS SECURES THE APPOINTMENT OF A LEGAL EXPERT - AND REQUESTS CALLS ON ERYTECH TO DEFER THE VOTE ON THE MERGER WITH PHERECYDES UNTIL AFTER THE LEGAL EXPERT'S REPORT HAS BEEN SUBMITTED
Legal Proceedings Report
2023-06-15 English
AKKADIAN PARTNERS OBTIENT LA NOMINATION D'UN EXPERT JUDICIAIRE - ET INVITE ERYTECH A REPORTER LE VOTE SUR LA FUSION AVEC PHERECYDES APRES LA REMISE DU RAPPORT DE L'EXPERT JUDICIAIRE
Legal Proceedings Report
2023-06-15 French
ERYTECH annonce que le tribunal de commerce a débouté Akkadian de sa demande de report du vote sur la fusion avec Pherecydes Pharma
Legal Proceedings Report
2023-06-14 French
ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma
Legal Proceedings Report
2023-06-14 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 mai 2023
Declaration of Voting Results & Voting Rights Announcements
2023-06-13 French
Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-06-13 English
AKKADIAN PARTNERS REJECTS THE LIQUIDATION OF ERYTECH IN THE EVENT THAT THE MERGER WITH PHERECYDES FAILS
Board/Management Information
2023-06-13 English
AKKADIAN PARTNERS DIT NON A LA LIQUIDATION D'ERYTECH EN CAS D'ECHEC DE LA FUSION AVEC PHERECYDES
Legal Proceedings Report
2023-06-13 French
ERYTECH Responds to Akkadian’s Disinformation
Governance Information
2023-06-12 English
ERYTECH répond à la désinformation d’Akkadian
Legal Proceedings Report
2023-06-12 French
Akkadian suggests to Erytech an alternative strategy to its merger with Pherecydes
M&A Activity
2023-06-07 English
Akkadian suggère à Erytech une stratégie alternative à sa fusion avec Pherecydes
Regulatory Filings
2023-06-07 French
ERYTECH annonce qu’Akkadian a initié une procédure visant à obtenir le report du vote de la fusion avec Pherecydes
M&A Activity
2023-06-05 French
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
Legal Proceedings Report
2023-06-05 English
Franchissement de seuils et déclaration d'intention
Major Shareholding Notification
2023-05-25 French
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
AGM Information
2023-05-24 English
ERYTECH annonce les modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 23 juin 2023
AGM Information
2023-05-24 French
ERYTECH annonce la mise à disposition du document d'exemption relatif au projet de rapprochement avec Pherecydes
Report Publication Announcement
2023-05-23 French
ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes
Report Publication Announcement
2023-05-23 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 15 mai 2023
Share Issue/Capital Change
2023-05-16 French
Monthly information related to total number of voting rights and shares composing the share capital _May 15, 2023
Regulatory Filings
2023-05-16 English
ERYTECH Provides Update on the Announced Combination with PHERECYDES
M&A Activity
2023-05-15 English
Point d'étape sur le rapprochement entre ERYTECH et PHERECYDES
M&A Activity
2023-05-15 French
Akkadian Partners Fund has acquired over a 5% shareholding and voting rights in Erytech and intends to vote against the merger between Erytech and Pherecydes
Major Shareholding Notification
2023-05-15 English
Akkadian Partners Fund acquiert une participation supérieure à 5% du capital et des droits de vote d'Erytech et entend s'opposer à la fusion entre Erytech et Pherecydes
Major Shareholding Notification
2023-05-15 French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-12 French
Monthly information related to total number of voting rights and shares composing the share capital _April 30, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-12 English
Akkadian Partners Fund has acquired over a 5% shareholding and voting rights in Erytech
Major Shareholding Notification
2023-05-12 English
Akkadian Partners Fund acquiert une participation supérieure à 5% du capital et des droits de vote d'Erytech
M&A Activity
2023-05-12 French
Franchissement de seuil
Major Shareholding Notification
2023-05-10 French
ERYTECH fait le point sur ses activités et sa position financière pour le premier trimestre 2023
Earnings Release Q1 2023
2023-05-09 French
ERYTECH Provides Business and Financial Update for the First Quarter of 2023
Earnings Release Q1 2023
2023-05-09 English
Franchissement de seuil
Major Shareholding Notification
2023-04-18 French
ERYTECH annonce l'approbation du transfert de sa cotation vers le Nasdaq Capital Market
Capital/Financing Update
2023-04-17 French
ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market
Delisting Announcement
2023-04-17 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 mars 2023
Regulatory Filings
2023-04-12 French
Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-04-12 English
Document d'Enregistrement Universel 2022
Annual Report (ESEF) FY 2022
2023-03-28 French
Document d'Enregistrement Universel 2022
Annual Report (ESEF) FY 2022
2023-03-28 French
ERYTECH fait le point sur ses activités et publie ses résultats du quatrième trimestre et de l’année 2022
Earnings Release Q4 2022
2023-03-22 French
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022
Earnings Release Q4 2022
2023-03-22 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 28 février 2023
Declaration of Voting Results & Voting Rights Announcements
2023-03-06 French
Monthly information related to total number of voting rights and shares composing the share capital _February 28, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-03-06 English
ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies
M&A Activity
2023-02-15 English
ERYTECH et PHERECYDES annoncent un projet de rapprochement stratégique en vue de créer un leader mondial de la phagothérapie
M&A Activity
2023-02-15 French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2023
Share Issue/Capital Change
2023-02-09 French
Monthly information related to total number of voting rights and shares composing the share capital _January 31, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-02-09 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2022
Share Issue/Capital Change
2023-01-09 French
Monthly information related to total number of voting rights and shares composing the share capital _December 31, 2022
Share Issue/Capital Change
2023-01-09 English
Franchissements de seuils
Declaration of Voting Results & Voting Rights Announcements
2023-01-06 French
Franchissement de seuils
Major Shareholding Notification
2023-01-02 French